Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arbutus Biopharma

3.55
+0.14004.11%
Pre-market: 3.630.0799+2.25%08:00 EDT
Volume:1.14M
Turnover:4.06M
Market Cap:679.75M
PE:-9.34
High:3.62
Open:3.36
Low:3.36
Close:3.41
Loading ...

BRIEF-Arbutus Provides 2025 Corporate And Financial Update

Reuters
·
13 Jan

Arbutus Biopharma provides 2025 corporate, financial update

TIPRANKS
·
13 Jan

Arbutus Provides 2025 Corporate and Financial Update

THOMSON REUTERS
·
13 Jan

Here’s Why Arbutus (ABUS) Surged in Q3

Insider Monkey
·
06 Dec 2024

Whitefort Capital sends letter to Arbutus Biopharma board of directors

TIPRANKS
·
03 Dec 2024

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Business Wire
·
03 Dec 2024

Arbutus Biopharma Highlights Hepatitis B Treatment Advances

TIPRANKS
·
26 Nov 2024

Chardan Research Adjusts Price Target on Arbutus Biopharma to $5 From $4.50, Maintains Buy Rating

MT Newswires Live
·
20 Nov 2024

Arbutus Biopharma Is Maintained at Buy by Chardan Capital

Dow Jones
·
20 Nov 2024

U.S. RESEARCH ROUNDUP- Apellis Pharmaceuticals, Energizer Holdings, Walmart

Reuters
·
20 Nov 2024

Arbutus Biopharma Corp : Chardan Capital Markets Raises Target Price to $5 From $4.5

THOMSON REUTERS
·
20 Nov 2024

Arbutus Biopharma price target raised to $5 from $4.50 at Chardan

TIPRANKS
·
20 Nov 2024

Arbutus Biopharma: Promising Developments and Positive Outlook Boost Buy Rating

TIPRANKS
·
19 Nov 2024

Arbutus Biopharma Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Nov 2024

Arbutus Biopharma’s Promising Breakthrough in Chronic Hepatitis B Treatment Justifies Buy Rating

TIPRANKS
·
18 Nov 2024

Arbutus Trial of Combination Therapy for Chronic Hepatitis B Shows 'Promising' Results

MT Newswires Live
·
16 Nov 2024

BRIEF-Arbutus & Barinthus Bio Announce New Data From The IM-PROVE II Trial

Reuters
·
16 Nov 2024

Arbutus Biopharma’s Promising cHBV Treatment Results

TIPRANKS
·
16 Nov 2024

Arbutus Biopharma’s Trial Boosts Hepatitis B Treatment

TIPRANKS
·
16 Nov 2024

Arbutus Biopharma announces new data from IM-PROVE I Phase 2a trial

TIPRANKS
·
16 Nov 2024